8 ud af 8 tidsskrifter valgt, søgeord (covid) valgt, emner højest 180 dage gamle, sorteret efter nyeste først.
147 emner vises.
51
Opinion: Toward Solving the Long COVID Puzzle
Medscape Infectious Diseases, 23.02.2024
Tilføjet 23.02.2024
In recent days, there were several important new reports that help explain the pathophysiology of long COVID. The new findings are summarized here. Medscape Medical News
Læs mere
52
Studie med 99 mio. deltagere: Alvorlige bivirkninger efter covid-19 vacciner er sjældne
Statens Serum Institut, 23.02.2024
Tilføjet 23.02.2024
Verdens største studie af covid-19 vaccinernes sikkerhed bekræfter, at alvorlige bivirkninger efter vaccination sjældne.
Læs mere
53
Application of the screening method for estimating COVID-19 vaccine effectiveness using routine surveillance data: Germany’s experience during the COVID-19 pandemic, July 2021 to March 2023
Nita Perumal, Viktoria Schönfeld and Ole Wichmann
Eurosurveillance latest updates, 23.02.2024
Tilføjet 23.02.2024
The screening method represents a simple, quick, and practical tool for estimating vaccine effectiveness (VE) using routine disease surveillance and vaccine coverage data, even if these data cannot be linked. In Germany, where notification data, laboratory testing data, and vaccine coverage data cannot be linked due to strict data protection requirements, the screening method was used to assess COVID-19 VE continuously between July 2021 and March 2023. During this period, when Delta and Omicron variants circulated, VE estimates were produced in real-time for different age groups and clinical outcomes. Here we describe the country’s overall positive experience using the screening method, including its strengths and limitations, and provide practical guidance regarding a few issues, such as case definition stringency, testing behaviour, and data stratification, that require careful consideration during data analysis and the interpretation of the results.
Læs mere
54
Wastewater-based reproduction numbers and projections of COVID-19 cases in three areas in Japan, November 2021 to December 2022
Shogo Miyazawa, Ting Sam Wong, Genta Ito, Ryo Iwamoto, Kozo Watanabe, Michiel van Boven, Jacco Wallinga and Fuminari Miura
Eurosurveillance latest updates, 23.02.2024
Tilføjet 23.02.2024
BackgroundWastewater surveillance has expanded globally as a means to monitor spread of infectious diseases. An inherent challenge is substantial noise and bias in wastewater data because of the sampling and quantification process, limiting the applicability of wastewater surveillance as a monitoring tool. AimTo present an analytical framework for capturing the growth trend of circulating infections from wastewater data and conducting scenario analyses to guide policy decisions. MethodsWe developed a mathematical model for translating the observed SARS-CoV-2 viral load in wastewater into effective reproduction numbers. We used an extended Kalman filter to infer underlying transmissions by smoothing out observational noise. We also illustrated the impact of different countermeasures such as expanded vaccinations and non-pharmaceutical interventions on the projected number of cases using three study areas in Japan during 2021–22 as an example. ResultsObserved notified cases were matched with the range of cases estimated by our approach with wastewater data only, across different study areas and virus quantification methods, especially when the disease prevalence was high. Estimated reproduction numbers derived from wastewater data were consistent with notification-based reproduction numbers. Our projections showed that a 10–20% increase in vaccination coverage or a 10% reduction in contact rate may suffice to initiate a declining trend in study areas. ConclusionOur study demonstrates how wastewater data can be used to track reproduction numbers and perform scenario modelling to inform policy decisions. The proposed framework complements conventional clinical surveillance, especially when reliable and timely epidemiological data are not available.
Læs mere
55
Notes from the Field: Reemergence of Mycoplasma pneumoniae Infections in Children and Adolescents After the COVID-19 Pandemic, United States, 2018-2024
Morbidity and Mortality Weekly Report (MMWR), 22.02.2024
Tilføjet 22.02.2024
This report describes an increase in Mycoplasma pneumoniae, a common cause of respiratory illness, beginning in fall 2023.
Læs mere
56
Italy Spent Around 45% Of EU COVID Recovery Cash Received So Far, Report Shows
Medscape Infectious Diseases, 22.02.2024
Tilføjet 22.02.2024
Italy has spent around 45% of the almost 102 billion euros ($110.7 billion) it has received so far from European Union COVID-19 recovery funds, short of a target set in... Reuters Health Information
Læs mere
57
Covid-19-smitte giver flere neurologiske diagnoser
Statens Serum Institut, 22.02.2024
Tilføjet 22.02.2024
I den brede danske befolkning blev der diagnosticeret flere neurologiske lidelser efter smitte med covid-19. Det viser en ny stor undersøgelse fra Statens Serum Institut, hvor der indgik knap 1,8 mio smittede danskere.
Læs mere
58
Study IDs Immune Abnormality Possibly Causing Long COVID
Medscape Infectious Diseases, 22.02.2024
Tilføjet 22.02.2024
Dysfunctional complement system proteins could explain chronic inflammation, fatigue, and other long COVID symptoms, leading to new treatments. Medscape Medical News
Læs mere
59
What to Know About COVID Rebound
Medscape Infectious Diseases, 22.02.2024
Tilføjet 22.02.2024
The CDC\'s Pragna Patel, MD, MPH, and Dallas Smith, PharmD, answer common questions on COVID-19 rebound cases and antiviral treatment. CDC Expert Commentary
Læs mere
60
Bias in vaccine effectiveness studies of clinically severe outcomes that are measured with low specificity: the example of COVID-19-related hospitalisation
Christian Holm Hansen
Eurosurveillance latest updates, 16.02.2024
Tilføjet 16.02.2024
Many vaccine effectiveness (VE) analyses of severe disease outcomes such as hospitalisation and death include ‘false’ cases that are not actually caused by the infection or disease under study. While the inclusion of such false cases inflate outcome rates in both vaccinated and unvaccinated populations, it is less obvious how they affect estimates of VE. Illustrating the main points through simple examples, this article shows how VE is underestimated when false cases are included as outcomes. Depending how the outcome indicator is defined, estimates of VE against severe disease outcomes, whose definition allows for the inclusion of false cases, will be biased downwards and may in certain circumstances approximate the same level as the VE against infection. The bias is particularly pronounced for vaccines that offer high levels of protection against severe disease outcomes but poor protection against infection. Analysing outcomes that are measured with low sensitivity generally does not cause bias in VE studies; defining outcome indicators that minimise the number of false cases rather than the number of missed cases is preferable in VE studies.
Læs mere
61
Epidemiology of reported cases of leptospirosis in the EU/EEA, 2010 to 2021
Julien Beauté, Francesco Innocenti, Aristos Aristodimou, Michaela Špačková, Caroline Eves, Natalia Kerbo, Ruska Rimhanen-Finne, Mathieu Picardeau, Mirko Faber, Georgios Dougas, Anna Margrét Halldórsdóttir, Sarah Jackson, Viktorija Leitēna, Anne Vergison, Maria Louise Borg, Roan Pijnacker, Małgorzata Sadkowska-Todys, João Vieira Martins, Lavinia Cipriana Rusu, Eva Grilc, Rosa M Estévez-Reboredo, Taina Niskanen and Therese Westrell
Eurosurveillance latest updates, 16.02.2024
Tilføjet 16.02.2024
BackgroundLeptospirosis is a zoonotic disease caused by bacteria of the genus Leptospira. Humans are infected by exposure to animal urine or urine-contaminated environments. Although disease incidence is lower in Europe compared with tropical regions, there have been reports of an increase in leptospirosis cases since the 2000s in some European countries. AimWe aimed to describe the epidemiology of reported cases of leptospirosis in the European Union/European Economic Area (EU/EEA) during 2010−2021 and to identify potential changes in epidemiological patterns. MethodsWe ran a descriptive analysis of leptospirosis cases reported by EU/EEA countries to the European Centre for Disease Prevention and Control with disease during 2010−2021. We also analysed trends at EU/EEA and national level. ResultsDuring 2010–2021, 23 countries reported 12,180 confirmed leptospirosis cases corresponding to a mean annual notification rate of 0.24 cases per 100,000 population. Five countries (France, Germany, the Netherlands, Portugal and Romania) accounted for 79% of all reported cases. The highest notification rate was observed in Slovenia with 0.82 cases per 100,000 population. Overall, the notification rate increased by 5.0% per year from 2010 to 2021 (95% CI: 1.2–8.8%), although trends differed across countries. ConclusionThe notification rate of leptospirosis at EU/EEA level increased during 2010−2021 despite including the first 2 years of the COVID-19 pandemic and associated changes in population behaviours. Studies at (sub)national level would help broaden the understanding of differences at country-level and specificities in terms of exposure to Leptospira, as well as biases in diagnosis and reporting.
Læs mere
62
2023/24 mid-season influenza and Omicron XBB.1.5 vaccine effectiveness estimates from the Canadian Sentinel Practitioner Surveillance Network (SPSN)
Danuta M Skowronski, Yuping Zhan, Samantha E Kaweski, Suzana Sabaiduc, Ayisha Khalid, Romy Olsha, Sara Carazo, James A Dickinson, Richard G Mather, Hugues Charest, Agatha N Jassem, Inès Levade, Maan Hasso, Nathan Zelyas, Ruimin Gao and Nathalie Bastien
Eurosurveillance latest updates, 16.02.2024
Tilføjet 16.02.2024
The Canadian Sentinel Practitioner Surveillance Network reports mid-season 2023/24 influenza vaccine effectiveness (VE) of 63% (95% CI: 51–72) against influenza A(H1N1)pdm09, lower for clade 5a.2a.1 (56%; 95% CI: 33–71) than clade 5a.2a (67%; 95% CI: 48–80), and lowest against influenza A(H3N2) (40%; 95% CI: 5–61). The Omicron XBB.1.5 vaccine protected comparably well, with VE of 47% (95% CI: 21–65) against medically attended COVID-19, higher among people reporting a prior confirmed SARS-CoV-2 infection at 67% (95% CI: 28–85).
Læs mere
63
Notes from the Field: Long COVID Prevalence Among Adults - United States, 2022
Morbidity and Mortality Weekly Report (MMWR), 16.02.2024
Tilføjet 16.02.2024
This report describes the prevalence of adults who reported ever experiencing Long COVID.
Læs mere
64
Laboratory Support for influenza and SARS-CoV-2 for Europe: AURORAE
ECDC
ECDC COVID-19 updates, 15.02.2024
Tilføjet 15.02.2024
AURORAE provides laboratory support for surveillance, preparedness and response to COVID-19 and influenza and strengthens the capacity for genomic epidemiology and public health bioinformatics through interdisciplinary training, which is crucial for response during a pandemic or unexpected major public health events.
Læs mere
65
Virus and Booster Apathy Could Be Fueling Long COVID
Medscape Infectious Diseases, 14.02.2024
Tilføjet 14.02.2024
\'Stupidest thing I\'ve ever done\': A lack of urgency surrounding virus spread and boosters may be triggering additional long COVID cases. Medscape Medical News
Læs mere
66
SARS-CoV-2 a Possible Trigger for Achalasia
Medscape Infectious Diseases, 13.02.2024
Tilføjet 13.02.2024
Researchers described cases of rapidly developing achalasia following COVID-19 and confirmed SARS-CoV-2 antigen in esophageal muscle tissue. Medscape Medical News
Læs mere
67
Protocol for a COVID-19 vaccine effectiveness estimation using health data registries, VEBIS multi-country study - Version 2.0
ECDC
ECDC COVID-19 updates, 13.02.2024
Tilføjet 13.02.2024
This protocol presents a common updated methodology to estimate vaccine effectiveness (VE) for COVID-19, using established health data registries in participating European Union and European Economic Area (EU/EEA) countries.
Læs mere
68
Communicable disease threats report, 4-10 February 2024, week 6
ECDC
ECDC Communicable Disease Threats Report, 9.02.2024
Tilføjet 9.02.2024
This issue of the ECDC Communicable Disease Threats Report (CDTR) the period 4-10 February 2024 and includes updates on avian influenza, measles, MERS-CoV, COVID-19, swine influenza, respiratory virus epidemiology, Western equine encephalitis, Hepatitis E, and the Chinese New Year.
Læs mere
69
Communicable disease threats report, 4-10 February 2024, week 6
ECDC
ECDC COVID-19 updates, 9.02.2024
Tilføjet 9.02.2024
This issue of the ECDC Communicable Disease Threats Report (CDTR) the period 4-10 February 2024 and includes updates on avian influenza, measles, MERS-CoV, COVID-19, swine influenza, respiratory virus epidemiology, Western equine encephalitis, Hepatitis E, and the Chinese New Year.
Læs mere
70
New Evidence Suggests Long COVID Could Be a Brain Injury
Medscape Infectious Diseases, 8.02.2024
Tilføjet 8.02.2024
Long-COVID sufferers of brain fog and memory loss exhibit elevated biomarkers consistent with brain injury. Medscape Medical News
Læs mere
71
De første covid-19-vacciner gav ikke flere bivirkninger
Statens Serum Institut, 8.02.2024
Tilføjet 8.02.2024
Særligt på sociale medier har der gennem længere tid floreret en myte om, at de første små partier af covid-19 vaccinen ikke havde samme kvalitet som de senere større partier, og at de derfor førte til langt flere bivirkninger. Denne myte punkteres nu i en ny stor undersøgelse fra Statens Serum Institut.
Læs mere
72
Core protocol for ECDC studies of COVID-19 vaccine effectiveness against hospitalisation with Severe Acute Respiratory Infection, laboratory-confirmed with SARS-CoV-2 or with seasonal influenza - Version 3.0
ECDC
ECDC COVID-19 updates, 6.02.2024
Tilføjet 6.02.2024
This core protocol for ECDC studies of VE against hospitalisation with SARI laboratory-confirmed with SARS-CoV-2 or with influenza, version 3.0, represents an update to the main elements for a multi-country hospital-based study of COVID-19 vaccine effectiveness in patients hospitalised with SARI, initially published as version 1.0 [5], updated to version 2.0 [6].
Læs mere
73
Data on COVID-19 vaccination in the EU/EEA
ECDC
ECDC COVID-19 updates, 2.02.2024
Tilføjet 2.02.2024
This downloadable data file contains information on COVID-19 vaccination in the EU/EEA since September 2023.
Læs mere
74
Early Estimates of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Attributable to Co-Circulating Omicron Variants Among Immunocompetent Adults - Increasing Community Access to Testing Program, United States, September 2023-January 2024
Morbidity and Mortality Weekly Report (MMWR), 2.02.2024
Tilføjet 2.02.2024
This report describes vaccine effectiveness for the updated COVID-19 vaccine in preventing symptomatic SARS-CoV-2 infection.
Læs mere
75
Respiratory Virus Surge: Diagnosing COVID-19 vs RSV, Flu
Medscape Infectious Diseases, 1.02.2024
Tilføjet 1.02.2024
Amid the current winter wave surge of respiratory virus cases, how challenging is it for physician\'s to distinguish between, diagnose, and treat COVID-19 vs RSV and influenza? Medscape Medical News
Læs mere
76
Vaccination coverage in the EU/EEA during Autumn 2023 campaigns
ECDC
ECDC COVID-19 updates, 26.01.2024
Tilføjet 26.01.2024
Nearly 20 million people aged 60 years and above received COVID-19 vaccines during the autumn / winter campaign in the EU/EEA
Læs mere
77
Interim COVID-19 vaccination coverage in the EU/EEA during the 2023–24 season campaigns
ECDC
ECDC COVID-19 updates, 26.01.2024
Tilføjet 26.01.2024
This report presents an interim description of COVID-19 vaccine coverage in the European Union/European Economic Area (EU/EEA) between 1 September 2023 and January 2024.
Læs mere
78
Age-dependent influenza infection patterns and subtype circulation in Denmark, in seasons 2015/16 to 2021/22
Hanne-Dorthe Emborg, Amanda Bolt Botnen, Jens Nielsen, Lasse S. Vestergaard, Frederikke Kristensen Lomholt, Charlotte Munkstrup, Karina Lauenborg Møller, Charlotte Kjelsø, Steen Hulthin Rasmussen and Ramona Trebbien
Eurosurveillance latest updates, 26.01.2024
Tilføjet 26.01.2024
BackgroundInfluenza was almost absent for 2 years following the implementation of strict public health measures to prevent the spread of SARS-CoV-2. The consequence of this on infections in different age groups is not yet known. AimTo describe the age groups infected with the influenza virus in 2021/22, the first post-pandemic influenza season in Denmark, compared with the previous six seasons, and subtypes circulating therein. MethodsInfection and hospitalisation incidences per season and age group were estimated from data in Danish registries. Influenza virus subtypes and lineages were available from samples sent to the National Influenza Centre at Statens Serum Institut. ResultsTest incidence followed a similar pattern in all seasons, being highest in 0–1-year-olds and individuals over 75 years, and lowest in 7–14-year-olds and young people 15 years to late twenties. When the influenza A virus subtypes A(H3N2) and A(H1N1)pdm09 co-circulated in seasons 2015/16 and 2017/18 to 2019/20, the proportion of A(H1N1)pdm09 was higher in 0–1-year-olds and lower in the over 85-year-olds compared with the overall proportion of A(H1N1)pdm09 in these seasons. The proportion of A(H3N2) was higher in the over 85 years age group compared with the overall proportion of A(H3N2). The 2016/17 and 2021/22 seasons were dominated by A(H3N2) but differed in age-specific trends, with the over 85 years age group initiating the 2016/17 season, while the 2021/22 season was initiated by the 15–25-year-olds, followed by 7–14-year-olds. ConclusionThe 2021/22 influenza season had a different age distribution compared with pre-COVID-19 pandemic seasons.
Læs mere
79
Authors’ response: Added value of backward contact tracing for COVID-19
Timo Louis Boelsums, Maaike Buskermolen and on behalf of all co-authors of the original article
Eurosurveillance latest updates, 26.01.2024
Tilføjet 26.01.2024
80
Underuse of Antiviral Drugs to Prevent Progression to Severe COVID-19 - Veterans Health Administration, March-September 2022
Morbidity and Mortality Weekly Report (MMWR), 26.01.2024
Tilføjet 26.01.2024
This report describes a review of immunosuppressed patients with nonsevere COVID-19 who were not treated with an antiviral drug.
Læs mere
81
Five Bold Predictions for Long COVID in 2024
Medscape Infectious Diseases, 25.01.2024
Tilføjet 25.01.2024
If even one of these comes true, long COVID sufferers could enjoy some much-needed relief. Medscape Medical News
Læs mere
82
Picture of COVID-19 in Europe Is Complex
Medscape Infectious Diseases, 24.01.2024
Tilføjet 24.01.2024
Infection rates are declining overall, but continuing vigilance is crucial, said WHO. Medscape Medical News
Læs mere
83
CDC Says JN.1 Variant Accounts for About 86% Of COVID Cases in US
Medscape Infectious Diseases, 24.01.2024
Tilføjet 24.01.2024
The U.S. Centers for Disease Control and Prevention (CDC) on Monday estimated COVID subvariant JN.1 to account for about 85.7% of cases in the United States, as of Jan.... Reuters Health Information
Læs mere
84
Forskere har fundet ud af, hvem der især blev ramt af senfølger efter covid-19
Statens Serum Institut, 23.01.2024
Tilføjet 23.01.2024
Personer over 35 år, kvinder, overvægtige og mennesker med lidelser som depression og astma var særligt udsatte for senfølger efter covid-19 infektion tidligt i pandemien, konkluderer ny undersøgelse.
Læs mere
85
Why Are Women More Likely to Get Long COVID?
Medscape Infectious Diseases, 20.01.2024
Tilføjet 20.01.2024
Emerging research showing links to female reproductive health may offer clues to why women experience long COVID at nearly twice the rate of men. Medscape Medical News
Læs mere
86
Time trends and modifiable factors of COVID-19 contact tracing coverage, Geneva, Switzerland, June 2020 to February 2022
Denis Mongin, Nils Bürgisser, the Covid-SMC Study Group and Delphine Sophie Courvoisier
Eurosurveillance latest updates, 19.01.2024
Tilføjet 19.01.2024
BackgroundContact tracing was one of the central non-pharmaceutical interventions implemented worldwide to control the spread of SARS-CoV-2, but its effectiveness depends on its ability to detect contacts. AimEvaluate the proportion of secondary infections captured by the contact tracing system in Geneva. MethodsWe analysed 166,892 concomitant infections occurring at the same given address from June 2020 until February 2022 using an extensive operational database of SARS-CoV-2 tests in Geneva. We used permutation to compare the total number of secondary infections occurring at the same address with that reported through manual contact tracing. ResultsContact tracing captured on average 41% of secondary infections, varying from 23% during epidemic peaks to 60% during low epidemic activity. People living in wealthy neighbourhoods were less likely to report contacts (odds ratio (OR): 1.6). People living in apartment buildings were also less likely to report contacts than those living in a house (OR: 1.1–3.1) depending on the SARS-CoV-2 variant, the building size and the presence of shops. This under-reporting of contacts in apartment buildings decreased during periods of mandatory wearing of face masks and restrictions on private gatherings. ConclusionContact tracing alone did not detect sufficient secondary infections to reduce the spread of SARS-CoV-2. Campaigns targeting specific populations, such as those in wealthy areas or apartment buildings, could enhance coverage. Additionally, measures like wearing face masks, improving ventilation and implementing restrictions on gatherings should also be considered to reduce infections resulting from interactions that may not be perceived as high risk.
Læs mere
87
Effectiveness of the adapted bivalent mRNA COVID-19 vaccines against hospitalisation in individuals aged ≥ 60 years during the Omicron XBB lineage-predominant period: VEBIS SARI VE network, Europe, February to August, 2023
Liliana Antunes, Clara Mazagatos, Iván Martínez-Baz, Verónica Gomez, Maria-Louise Borg, Goranka Petrović, Róisín Duffy, François E Dufrasne, Ralf Dürrwald, Mihaela Lazar, Ligita Jancoriene, Beatrix Oroszi, Petr Husa, Jennifer Howard, Aryse Melo, Francisco Pozo, Gloria Pérez-Gimeno, Jesús Castilla, Ausenda Machado, Aušra Džiugytė, Svjetlana Karabuva, Margaret Fitzgerald, Sébastien Fierens, Kristin Tolksdorf, Silvia-Odette Popovici, Auksė Mickienė, Gergő Túri, Lenka Součková, Nathalie Nicolay, Angela MC Rose and on behalf of the European Hospital Vaccine Effectiveness Group
Eurosurveillance latest updates, 19.01.2024
Tilføjet 19.01.2024
We conducted a multicentre hospital-based test-negative case–control study to measure the effectiveness of adapted bivalent COVID-19 mRNA vaccines against PCR-confirmed SARS-CoV-2 infection during the Omicron XBB lineage-predominant period in patients aged ≥ 60 years with severe acute respiratory infection from five countries in Europe. Bivalent vaccines provided short-term additional protection compared with those vaccinated > 6 months before the campaign: from 80% (95% CI: 50 to 94) for 14–89 days post-vaccination, 15% (95% CI: −12 to 35) at 90–179 days, and lower to no effect thereafter.
Læs mere
88
Study Estimates Post-COVID Risk for Alopecia Areata
Medscape Infectious Diseases, 15.01.2024
Tilføjet 15.01.2024
The incidence of alopecia areata in patients with COVID-19 was significantly higher than that in the uninfected controls, in a large Korean cohort study. MDedge News
Læs mere
89
RespiCast: the new European Respiratory Diseases Forecasting Hub
ECDC
ECDC COVID-19 updates, 15.01.2024
Tilføjet 15.01.2024
The European Respiratory Diseases Forecasting Hub (RespiCast) is open for weekly submission of several respiratory disease indicators such as influenza-like-illness, acute respiratory infection and COVID-19.
Læs mere
90
Impact of sex and gender on post-COVID-19 syndrome, Switzerland, 2020
Caroline E Gebhard, Claudia Sütsch, Pimrapat Gebert, Bianca Gysi, Susan Bengs, Atanas Todorov, Manja Deforth, Philipp K Buehler, Alexander Meisel, Reto A Schuepbach, Annelies S Zinkernagel, Silvio D Brugger, Claudio Acevedo, Dimitri Patriki, Benedikt Wiggli, Jürg H Beer, Andrée Friedl, Raphael Twerenbold, Gabriela M Kuster, Hans Pargger, Sarah Tschudin-Sutter, Joerg C Schefold, Thibaud Spinetti, Chiara Henze, Mina Pasqualini, Dominik F Sager, Lilian Mayrhofer, Mirjam Grieder, Janna Tontsch, Fabian C Franzeck, Pedro D Wendel Garcia, Daniel A Hofmaenner, Thomas Scheier, Jan Bartussek, Ahmed Haider, Muriel Grämer, Nidaa Mikail, Alexia Rossi, Núria Zellweger, Petra Opić, Angela Portmann, Roland von Känel, Aju P Pazhenkottil, Michael Messerli, Ronny R Buechel, Philipp A Kaufmann, Valerie Treyer, Martin Siegemund, Ulrike Held, Vera Regitz-Zagrosek and Catherine Gebhard
Eurosurveillance latest updates, 12.01.2024
Tilføjet 12.01.2024
BackgroundWomen are overrepresented among individuals with post-acute sequelae of SARS-CoV-2 infection (PASC). Biological (sex) as well as sociocultural (gender) differences between women and men might account for this imbalance, yet their impact on PASC is unknown. AimWe assessed the impact of sex and gender on PASC in a Swiss population. MethodOur multicentre prospective cohort study included 2,856 (46% women, mean age 44.2 ± 16.8 years) outpatients and hospitalised patients with PCR-confirmed SARS-CoV-2 infection. ResultsAmong those who remained outpatients during their first infection, women reported persisting symptoms more often than men (40.5% vs 25.5% of men; p
Læs mere
91
Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing COVID-19-Related Thromboembolic Events Among Medicare Enrollees Aged ≥65 Years and Those with End Stage Renal Disease - United States, September 2022-March 2023
Morbidity and Mortality Weekly Report (MMWR), 12.01.2024
Tilføjet 12.01.2024
This report describes how bivalent COVID-19 vaccines were nearly 50% effective in preventing COVID-19-related thromboembolic events among adults aged 65 and older and those on dialysis.
Læs mere
92
Spain Makes Masks Mandatory in Healthcare Centres Amid Flu, COVID Peak
Medscape Infectious Diseases, 12.01.2024
Tilføjet 12.01.2024
Spanish Health Minister Monica Garcia made wearing masks mandatory in healthcare centres around the country from Wednesday as the country faces a peak of flu and COVID-19... Reuters Health Information
Læs mere
93
Relative vaccine effectiveness against COVID-19 hospitalisation in persons aged ≥ 65 years: results from a VEBIS network, Europe, October 2021 to July 2023
Mario Fontán-Vela, Esther Kissling, Nathalie Nicolay, Toon Braeye, Izaak Van Evercooren, Christian Holm Hansen, Hanne-Dorthe Emborg, Massimo Fabiani, Alberto Mateo-Urdiales, Ala'a AlKerwi, Susanne Schmitz, Jesús Castilla, Iván Martínez-Baz, Brechje de Gier, Susan Hahné, Hinta Meijerink, Jostein Starrfelt, Baltazar Nunes, Constantino Caetano, Tarik Derrough, Anthony Nardone, Susana Monge and VEBIS-Lot4 working group
Eurosurveillance latest updates, 5.01.2024
Tilføjet 5.01.2024
To monitor relative vaccine effectiveness (rVE) against COVID-19-related hospitalisation of the first, second and third COVID-19 booster (vs complete primary vaccination), we performed monthly Cox regression models using retrospective cohorts constructed from electronic health registries in eight European countries, October 2021–July 2023. Within 12 weeks of administration, each booster showed high rVE (≥ 70% for second and third boosters). However, as of July 2023, most of the relative benefit has waned, particularly in persons ≥ 80-years-old, while some protection remained in 65–79-year-olds.
Læs mere
94
Early COVID-19 vaccine effectiveness of XBB.1.5 vaccine against hospitalisation and admission to intensive care, the Netherlands, 9 October to 5 December 2023
C Henri van Werkhoven, Anne-Wil Valk, Bente Smagge, Hester E de Melker, Mirjam J Knol, Susan JM Hahné, Susan van den Hof and Brechje de Gier
Eurosurveillance latest updates, 5.01.2024
Tilføjet 5.01.2024
We present early vaccine effectiveness (VE) estimates of the 2023 seasonal COVID-19 XBB.1.5 vaccine against COVID-19 hospitalisation and admission to an intensive care unit (ICU) in previously vaccinated adults ≥ 60 years in the Netherlands. We compared vaccination status of 2,050 hospitalisations including 92 ICU admissions with age group-, sex-, region- and date-specific population vaccination coverage between 9 October and 5 December 2023. VE against hospitalisation was 70.7% (95% CI: 66.6–74.3), VE against ICU admission was 73.3% (95% CI: 42.2–87.6).
Læs mere
95
Covid-19-smittebølge har toppet
Statens Serum Institut, 3.01.2024
Tilføjet 3.01.2024
De seneste ugers udbredte smitte med fem forskellige luftvejssygdomme ser nu ud til at have toppet for flere af sygdommene. Særligt covid-19, der har fyldt mest, ser ud til at være på retur, og hvis udviklingen holder stik, vil det forventeligt kunne mærkes på sygdomsbilledet de kommende uger.
Læs mere
96
Long COVID Has Caused Thousands of US Deaths: New CDC Data
Medscape Infectious Diseases, 3.01.2024
Tilføjet 3.01.2024
Fresh estimates from the CDC show a growing death tally from long COVID —– with numbers expected to increase as diagnostic expertise improves. Medscape Medical News
Læs mere
97
Long COVID: New Info on Who Is Most Likely to Get It
Medscape Infectious Diseases, 27.12.2023
Tilføjet 27.12.2023
Fresh research and clinical anecdotes have given experts a much clearer picture of which patients are most likely to develop long COVID. Medscape Medical News
Læs mere
98
CDC Says JN.1 Variant Accounts for 39%-50% Of COVID Cases in US
Medscape Infectious Diseases, 26.12.2023
Tilføjet 26.12.2023
The U.S. Centers for Disease Control and Prevention (CDC) said on Friday that COVID subvariant JN.1 accounts for 39% to 50% of cases in the United States as of Dec. 23,... Reuters Health Information
Læs mere
99
Monoclonal Antibodies: A New Treatment for Long COVID?
Medscape Infectious Diseases, 22.12.2023
Tilføjet 22.12.2023
A small study generated impressive results. Medscape Medical News
Læs mere
100
Influenza, Updated COVID-19, and Respiratory Syncytial Virus Vaccination Coverage Among Adults - United States, Fall 2023
Morbidity and Mortality Weekly Report (MMWR), 21.12.2023
Tilføjet 21.12.2023
This report describes influenza, updated COVID-19, and respiratory syncytial virus vaccination coverage among adults.
Læs mere